SLS
Sellas Life Sciences Group Inc
11.70$
+3.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -23.1% | +292.9% | -38.1% | +75.3% | -26.7% | +79.9% | -7.6% | +59.6% | +52.0% | +45.7% | +27.3% | |
| – | -39.0% | +577.8% | -42.8% | +95.4% | -32.1% | +95.8% | -7.9% | +66.6% | +53.3% | +47.8% | +28.2% | |
| – | -36.3% | +627.9% | -50.3% | +129.9% | -34.0% | +104.5% | -10.9% | +75.6% | +61.8% | +49.1% | +29.1% | |
| – | -36.3% | +627.9% | -50.3% | +129.9% | -34.0% | +104.5% | -10.9% | +75.6% | +61.8% | +49.1% | +29.1% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | +19.2% | +3.9% | -17.2% | -13.1% | -6.1% | -27.8% | -14.5% | -3.8% | +26.1% | -9.5% | +14.2% | |
| – | +17.0% | +5.1% | -16.6% | -11.9% | -10.4% | -27.6% | -12.9% | -1.2% | +18.4% | -8.0% | +17.2% | |
| – | -4.3% | +9.4% | +8.8% | +8.5% | -5.6% | +3.1% | +3.4% | +3.3% | -9.2% | +3.3% | +3.2% | |
| – | +29.9% | +31.4% | -14.5% | -28.2% | -23.0% | +7.3% | -11.2% | -30.9% | +27.9% | +23.2% | -15.1% | |
| – | – | – | -69.9% | +445.6% | -40.4% | +193.3% | -5.8% | +74.5% | +55.3% | +51.6% | +28.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +8.6% | +45.5% | +28.6% | +18.4% | +8.4% | +18.6% | +12.3% | +10.0% | +41.2% | +12.7% | +9.7% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.